A multicentre, retrospective study in patients with multiple sclerosis treated with natalizumab in real-world setting in Japan
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REFIND Study
- 30 Jul 2021 New trial record
- 27 Jul 2021 Status changed from not yet recruiting to recruiting.